No Picture
News

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder

PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy

SOUTH SAN FRANCISCO, Calif., Feb. 20, 202… […]

No Picture
News

Nucleus Biologics Develops cGMP CMRL Media and zIF(TM) Xeno-Free Supplement for Robust Human Islet Cell Culture

SAN DIEGO, Feb. 18, 2020 /PRNewswire/ — Nucleus Biologics, a leader in precision cell culture, announced today a complete line of cGMP grade media and a new supplement to enable improved insulin response and standardized processing of human pancre… […]

No Picture
News

Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

– Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms- Onvansertib-induced decreases in circulating tumor cells (CTCs) is a surrogate for ef… […]

No Picture
News

Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program

SAN JOSE, Calif., Feb. 12, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Cone… […]

No Picture
News

Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002

Signatera test used for patient selection and monitoring to accelerate molecular proof of concept

CAMBRIDGE, Mass. and SAN CARLOS, Calif., Feb. 11, 2020 /PRNewswire/ — Elicio Therapeutics, a next generation immuno-oncology company, and Natera, I… […]

No Picture
News

VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

When given together with VistaGen’s oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ… […]

No Picture
News

Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn’s and Colitis Organization (ECCO)

NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company’s oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, a… […]

No Picture
News

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson’s Disease Patients

Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a clinic… […]

No Picture
News

Helix and Renown Health publish largest-ever genome-wide rare variant analysis on thousands of clinical phenotypes and over 70,000 exomes

The study demonstrates how population-scale exome sequencing efforts, such as the Healthy Nevada Project, the largest health system-driven clinical exome sequencing initiative, improve our understanding of the human genome.

SAN MATEO, Calif. and RENO… […]

No Picture
News

Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients

– All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients- Tumor regression occurred across all major KRAS mutation types in CRC, … […]